

# Question 13

- Which of the following regarding the treatment of symptomatic PAD is correct?
  - A. Participation in a supervised exercise training program leads to an almost doubling of the claudication-free distance
  - B. Patients with PAD should be treated aggressively with lipid-lowering therapy to achieve a target LDL<100 mg/dl
  - C. ABI <0.9 in hypertensive patients is predictor of increased mortality
  - D. Both pentoxifylline and cilostazol are FDA approved for the treatment of intermittent claudication

# Question 13

- Which of the following regarding the treatment of symptomatic PAD is correct?
  - A. Participation in a supervised exercise training program leads to an almost doubling of the claudication-free distance
  - B. Patients with PAD should be treated aggressively with lipid-lowering therapy to achieve a target LDL<100 mg/dl
  - C. ABI <0.9 in hypertensive patients is predictor of increased mortality
  - D. Both pentoxifylline and cilostazol are FDA approved for the treatment of intermittent claudication